Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Sales: 2012-2025

Historic Return on Sales for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to -1.25%.

  • Enanta Pharmaceuticals' Return on Sales rose 46.00% to -1.25% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.25%, marking a year-over-year increase of 46.00%. This contributed to the annual value of -1.25% for FY2025, which is 46.00% up from last year.
  • Enanta Pharmaceuticals' Return on Sales amounted to -1.25% in Q3 2025, which was up 11.64% from -1.42% recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Return on Sales ranged from a high of -0.94% in Q1 2021 and a low of -1.88% during Q4 2023.
  • Moreover, its 3-year median value for Return on Sales was -1.60% (2024), whereas its average is -1.60%.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Return on Sales slumped by 107bps in 2021, and later surged by 46bps in 2025.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Return on Sales stood at -1.24% in 2021, then dropped by 23bps to -1.47% in 2022, then tumbled by 41bps to -1.88% in 2023, then rose by 30bps to -1.57% in 2024, then surged by 46bps to -1.25% in 2025.
  • Its Return on Sales was -1.25% in Q3 2025, compared to -1.42% in Q2 2025 and -1.49% in Q1 2025.